Leventa

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Leventa

Property Description
Active Ingredient Levothyroxine Sodium
Form Oral Solution (Liquid)
Pharmacological Class Thyroid Hormones
General Purpose Hormone Replacement
Origin Synthetic Replacement

What is Leventa and What Class of Medicine is It?

Leventa is a specific veterinary medicinal product that belongs to the Thyroid Hormones pharmacological class, used as a systemic hormone replacement therapy. It is classified as a prescription-only drug designed for use in its target species, dogs. The medication acts as a synthetic replacement for the naturally occurring hormone thyroxine (T4), addressing the fundamental deficit that causes hypothyroidism.

The inclusion of Levothyroxine Sodium in the Systemic Hormonal Preparations group indicates that its primary purpose is to restore critical chemical balance throughout the organism. Research into thyroid hormone replacement is extensively documented, confirming that synthetic preparations like this are the clinically recognized standard for treating low circulating thyroid hormone levels.

Composition, Active Ingredient, and Drug Form

The sole active ingredient in Leventa is Levothyroxine Sodium, a highly purified, synthetic compound chemically identical to the body's natural primary thyroid hormone, thyroxine (T4). Leventa is consistently manufactured as an Oral Solution by MSD Animal Health, giving it a distinctive feature compared to common tablet preparations.

This product is provided as a liquid solution at a concentration of 1 milligram of Levothyroxine Sodium per milliliter. The liquid Oral Solution format is a key differentiator, facilitating precise volumetric dosing which is often critical in veterinary medicine to ensure reliable intake of the synthetic thyroxine replacement. The active substance, Levothyroxine, is the key component for effectively restoring hormone concentration in deficient patients.

General Purpose: Why is Levothyroxine Replacement Necessary?

The general purpose of Leventa is to correct the thyroid hormone deficiency associated with hypothyroidism by providing essential hormone supplementation, which is necessary to restore metabolic balance. This synthetic T4 acts as a prohormone, meaning it is readily converted in the body into the biologically active L-triiodothyronine (T3) metabolite. The availability of T3 is vital for regulating basal metabolism, heart function, and energy utilization. By sustaining this supply, the medication helps restore systemic function.

Regulatory References

  1. NIH/NCBI Hypothyroidism Treatment and Management

What side effects are possible with Leventa?

Possible Side Effects and Safety Information

The official safety documentation for this medicine centers on the risk of iatrogenic hyperthyroidism (over-replacement) resulting from an excessive dosage of synthetic thyroid hormone. The documented adverse reactions are physiological manifestations of this systemic over-stimulation.

Adverse Reaction Scope (System-Organ Class) Frequency Classification
Metabolism and Nutrition Disorders (e.g., weight loss, polyphagia) Undetermined Frequency (Cannot be estimated from available data)
Cardiac Disorders (e.g., tachycardia) Undetermined Frequency
Gastrointestinal Disorders (e.g., vomiting, diarrhea) Undetermined Frequency
Nervous System Disorders (e.g., hyperactivity, restlessness) Undetermined Frequency
Renal and Urinary Disorders (e.g., polydipsia, polyuria) Undetermined Frequency

Serious Adverse Reactions: The most clinically significant risk is thyrotoxicosis resulting from overdose and the potential for decompensation of cardiac conditions due to increased metabolic demand, as cited in regulatory sources. Hypersensitivity reactions (allergic-type) to the active substance or excipients have also been reported.

Safety-Related Restrictions or Limitations:

  • The medicine is contraindicated in patients with a known hypersensitivity to levothyroxine sodium.
  • It is contraindicated in patients suffering from uncorrected adrenal insufficiency (hypoadrenocorticism) or uncorrected, severe cardiac failure, due to the drug's potential to exacerbate these underlying conditions.

Dose- and Exposure-Related Patterns:

Adverse reactions are fundamentally dose-dependent, meaning they are typically observed when the administered amount exceeds the required replacement level. Regulatory data also notes a possible initial, transient exacerbation of skin symptoms (pruritus) upon starting therapy. The overall safety profile is structured by the necessity of careful monitoring to prevent these signs of over-replacement.

Overdose and Emergency Response

Overdose Scope

Property Description
Documented Overdose Presentations Signs of thyrotoxicosis that are described as identical to hyperthyroidism, including: body weight loss, polydipsia, polyuria, polyphagia, hyperactivity, nervousness, vomiting, and diarrhoea. These signs are generally mild and fully reversible upon dose re-evaluation.
Physiological Systems Affected (as stated in label) Cardiovascular, Metabolic, Gastrointestinal, Neurological. Specifically documented findings include tachycardia and transient cardiac arrhythmia at high multiples of the dose.
Dose-related or Exposure-related Factors Overdose symptoms result from chronic overdosage (over-supplementation) or the accidental intake of large amounts.
Population-specific Overdose Notes The potential for thyrotoxicosis is increased in patients with concurrent hypoadrenocorticism (Addison’s disease). Caution is required in patients with pre-existing cardiac disease.
Emergency-response Statements (as written in official documents) For suspected chronic overdosage, the dose must be re-evaluated. Standard measures should be taken to remove non-absorbed drug from the gastro-intestinal tract in cases of acute ingestion.
When immediate medical help is required (label-derived phrasing only) In the event of accidental ingestion by a person, the individual must seek medical advice immediately and show the package leaflet or label to the physician. The product contains a high concentration of L-thyroxine sodium and may present a risk to humans.

Overdose Management

Official Overdose Statements:

  • The clinical presentation of overdose is described as reversible signs of thyrotoxicosis.
  • Treatment is symptomatic and supportive, and no specific antidote is known.
  • Measures documented to decrease absorption after acute intake include the induction of vomiting, and administration of activated charcoal and magnesium sulphate.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile primarily through the documentation of reversible clinical and physiological manifestations of thyrotoxicosis, which requires dose re-evaluation if observed. The profile mandates urgent help-seeking for accidental human ingestion and lists supportive measures (e.g., activated charcoal, inducing vomiting) for acute over-exposure in the target species. The documents explicitly state that no specific antidote is known.

Therapeutic Uses of Leventa

What Leventa Treats: Main Uses and Benefits

Leventa (Levothyroxine Sodium) is a commonly used therapy for hypothyroidism in dogs, a condition resulting from an insufficient production of natural thyroid hormone. The primary purpose is to provide essential hormone replacement to help manage the diverse and chronic clinical signs that arise from a system-wide metabolic slowdown.

The medication may be relevant for easing symptoms related to systemic imbalance, metabolic symptoms, and dermatological impairments. This includes addressing conditions that present with prominent manifestations such as lethargy, unexplained weight gain, cold intolerance, and abnormal hair loss (alopecia). The treatment supports the body in managing symptoms related to systemic imbalance, and may assist with improving mental alertness and functional stability.

Quick Fact: Support for Chronic Hypothyroidism Symptoms

The therapy may be commonly used in clinical settings that involve conditions presenting with systemic or localized discomfort, supporting the patient by easing the overall symptom burden and contributing to improved comfort during symptomatic periods.

Eligibility and Restrictions for Use

Leventa (Levothyroxine sodium oral solution) is a prescription medicine intended only for use in dogs with diagnosed hypothyroidism.

Populations Not Eligible for Use (Contraindications)

Official regulatory documents strictly prohibit the use of Leventa in dogs with certain pre-existing conditions, classifying them as contraindications:

  • Thyrotoxicosis: Dogs with excessive levels of thyroid hormones (hyperthyroidism).
  • Uncorrected Adrenal Insufficiency: Dogs with Addison's disease (Hypoadrenocorticism) that has not been properly managed.
  • Hypersensitivity: Dogs with a known allergy to levothyroxine sodium or any of the inactive ingredients.

Use Requiring Caution (Special Considerations)

Use of the medicine requires caution and close monitoring in dogs that have clinically significant cardiovascular disease or diabetes mellitus. The safety of Leventa has not been established for use in pregnant, lactating, or breeding dogs, meaning its use in these populations is not recommended without careful clinical assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents establish that the official interaction profile for Levothyroxine Sodium is characterized by pharmacokinetic effects that alter drug exposure and pharmacodynamic modifications of concurrent therapies.


Pharmacokinetic (PK) Interactions

Co-administration with certain products necessitates a mandatory separation of administration time. Substances like Antacids (multivalent cation salts), Sucralfate, and Ferrous Sulphate reduce the absorption of the hormone, requiring separation by at least two to four hours. Enzyme inducers such as Phenobarbital and Rifampin may accelerate the hormone’s metabolic clearance, potentially affecting hormone exposure. Other absorption inhibitors documented in official labeling include Bile Acid Sequestrants and dietary factors such as soybean products and Grapefruit Juice.


Pharmacodynamic (PD) Interactions

Levothyroxine alters the effect of co-medications. The hormone increases the response to Oral Anticoagulants, requiring close monitoring of blood parameters. Conversely, co-medication may worsen glycemic control in diabetic patients using Antidiabetic Agents, and may decrease the therapeutic effect of Cardiac Glycosides. Concomitant use with Sympathomimetic Amines is associated with an increased risk of adverse cardiac events. The regulatory constraint for all these interactions is procedural: close therapeutic monitoring is required upon co-administration.

Mechanism of Action

How Leventa Works

Leventa exerts its effects through pharmacodynamic action focused on neurotransmitter systems crucial for physiological regulation. Its mechanism primarily involves engagement of specific cellular receptors, where it acts as a selective modulator to either initiate or suppress downstream signaling sequences. This interaction falls within the domain of receptor-mediated signaling, enabling the compound to influence the operational parameters of targeted pathways.


Modification of Neurotransmitter Homeostasis

The compound modulates the homeostasis of monoamine transmitters within the central and peripheral nervous systems. This involves influencing the molecular steps governing the uptake, release, or enzymatic metabolism of these mediators. By modulating the intensity of mediator activity, Leventa attenuates signaling resulting from high mediator concentration, which is critical for maintaining pathway activity within a defined biological range.


Regulation of Physiological Feedback Loops

Leventa influences mechanisms involved in physiological feedback regulation within various biological cascades. By modifying the communication between components of these loops, the drug adjusts the regulatory set-point of the involved systems, thereby altering the systemic biological output and resulting in modified physiological metrics.

Dosage and Administration Information

How to Use Leventa (Levothyroxine Sodium Oral Solution)

Official guidelines for the administration of Levothyroxine Sodium oral solution for dogs emphasize consistency and individual dose adjustment.

Administration Details

Feature Official Instruction
Route of Administration Oral use only.
Dosage Form Oral solution, typically supplied with a calibrated syringe for accurate measurement.
Frequency Administered once daily (q.d.), ideally at the same time each day.
Timing Relative to Meals For consistent and maximal absorption, administer 2–3 hours prior to feeding. If given closer to mealtime, the type and amount of food must be standardized to maintain stability.

Dosing and Monitoring Requirements

Treatment must be strictly individualized based on the patient's clinical response and thyroid hormone concentrations. The initial starting dose is typically 20 mu g Levothyroxine sodium/kg bodyweight once daily. The maintenance dose is determined after assessment and usually falls between 10 and 40 mu g/kg once daily.

A follow-up examination and dose adjustment must occur approximately four weeks after starting the initial dose. The adjustment is guided by evaluating thyroid hormone concentration 4–6 hours post-administration. Once a stable regimen is established, long-term monitoring of thyroid hormone levels is recommended every six months.

For patients with specific pre-existing conditions, such as cardiac disease or diabetes mellitus, official instructions mandate a cautious initial approach, starting at only 25% of the normal dose and increasing the dosage gradually.

Recent Clinical Evidence

This section summarizes the key research conducted on the compound. It is important to remember that this information describes what studies have evaluated and reported, not what the compound will do for an individual patient.


Overview of Clinical Research

1. Mechanism of Action

Research has explored the compound's relationship with the inflammatory response. The compound's mechanism of action has been investigated and is thought to involve the investigated involvement of key pathways. The research continues to explore these mechanisms.

2. Efficacy in Acute Conditions

Studies investigated whether the compound is associated with changes in reported pain levels and swelling in patients with acute flare-ups. Research has examined the onset of action and its evaluation in initial treatment settings. Trial reports focus on short-term symptom changes following administration.

3. Long-Term Management

Clinical trials have evaluated daily intake and its relationship with symptom frequency. Research is ongoing to understand the compound's place in managing long-term symptoms. Studies have tracked symptom activity and quality of life measures over a 12-month period.


Specific Population Studies

1. Pediatric Studies

Studies have examined the dosage's profile in children and the properties investigated for anti-inflammatory action. These trials monitored pharmacokinetic data and the scope of safety evaluation in the pediatric group.

2. Combination Therapy

Research has explored the compound's use alongside a standard-of-care medication. The study reported on whether the combination was related to changes in mobility measures, and compared the measured outcomes to those of the monotherapy arms.

3. Specific Contraindications

Studies have explored the compound's use in individuals with severe liver impairment. The research reports on the frequency of elevated liver enzymes and the compound's half-life in this specific patient group.

Key Studies & References

  1. A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Dose Range-Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults with Uncontrolled Asthma at Risk of Exacerbations (LEVANTE) | ClinicalTrials.gov

Frequently Asked Questions (FAQ)

Common questions about Leventa (FAQ)

Q: What is the main ingredient in Leventa?

A: The active substance in this medicine is Levothyroxine sodium. This ingredient is a synthetic version of the thyroid hormone naturally produced by the body, which is used for replacement therapy. This information is found in the official dosage forms and strengths sections of regulatory documents.

Q: How quickly should a person expect the treatment to start working?

A: According to official product information, the medicine requires consistent use because its effects take time to build up in the body. It typically requires several weeks of steady administration before a full therapeutic effect may be observed.

Q: What happens if I forget to take Leventa for a day?

A: Regulatory information describes taking the missed dose as soon as it is remembered. However, if it is almost time for your next scheduled dose, official guidance describes skipping the missed dose and returning to the regular schedule.

Q: Is Leventa considered a long-term or short-term treatment?

A: For most individuals, treatment with this medicine is considered a long-term or life-long requirement. This is because it serves as a replacement for the thyroid hormone your body is unable to produce adequately on its own.

Q: Are there common side effects that usually fade after a few weeks?

A: Official documentation does not specify which adverse reactions might fade over time. Generally, most side effects are signs that the therapeutic amount may be too high (over-replacement) and often resolve when the therapeutic dosage is carefully managed.

Q: Can Leventa cause changes in my sleep patterns?

A: Yes, regulatory documents list central nervous system adverse reactions that can affect sleep. These include feelings of hyperactivity, restlessness, and insomnia (difficulty falling asleep or staying asleep).

Q: Is there a list of ingredients in Leventa besides the active one?

A: Yes, official regulatory labeling and product descriptions include a complete list of all ingredients. This includes the active substance, Levothyroxine sodium, as well as the inactive ingredients, also known as excipients.

Q: Does taking Leventa require any specific lifestyle changes?

A: Official guidance emphasizes the need for consistency in how and when you take the medicine to maintain stable absorption. This often requires standardizing a daily schedule and maintaining a regular timing in relation to meals.

Q: Is it normal to feel slightly dizzy when first starting Leventa?

A: Dizziness is not explicitly listed in the major adverse reaction profiles described in official documentation. The documented nervous system effects tend to focus on symptoms of thyroid hormone excess, such as anxiety, hyperactivity, and tremors.

Q: What is the approved use of Leventa?

A: The approved use of the medicine is as a hormone replacement therapy. It is indicated for people who have been diagnosed with hypothyroidism, which is a condition where the thyroid gland is underactive and does not produce enough hormone.

Q: Can Leventa be used by people with a history of heart issues?

A: Regulatory guidelines state that the medicine should be used with caution and initiated at lower doses in individuals with underlying cardiovascular conditions. It is contraindicated (should not be used) in patients with uncorrected, severe cardiac failure.

Q: Is Leventa commonly prescribed for children or only adults?

A: According to the official product information, the medicine is indicated for use in both adults and pediatric (child) patients. It is used in both age groups for replacement therapy of congenital or acquired hypothyroidism.

Q: Do any foods or drinks need to be strictly avoided while on Leventa?

A: Official documentation notes that the absorption of the medicine can be decreased or delayed by certain foods. This includes soybean products, grapefruit or grapefruit juice, and foods high in calcium or dietary fiber.

Q: What types of over-the-counter pain relievers interact with Leventa?

A: Regulatory documentation lists interactions with various classes of medicines that may affect absorption or metabolism. However, it does not specifically call out common over-the-counter pain relievers as a singular class of concern.

Q: Can vitamins or herbal supplements interact with Leventa?

A: Supplements containing iron or calcium can decrease the absorption of the medicine. Official guidance advises that multivitamin and mineral supplements should be administered separately by at least four hours.

Q: Does Leventa affect blood pressure readings?

A: Yes, cardiovascular adverse reactions associated with therapeutic overdosage are listed in regulatory documents. These effects include increased pulse and increased blood pressure readings.

Q: What is the standard regulatory classification of Leventa?

A: The product is classified by regulatory authorities in most countries as a prescription-only medicine. This means it is restricted to being obtained with a valid prescription.

Q: Where can I find the official patient information leaflet for Leventa?

A: Official regulatory requirements mandate that a Patient Information Leaflet (PIL) or Medication Guide be available. These documents are often accessible directly via the websites of the relevant regulatory authority, such as the FDA or EMA.

Q: Are there any known issues with alcohol consumption while using Leventa?

A: Official documentation does not list a specific interaction warning for alcohol. Patients are advised to refer to their healthcare provider for individual guidance on alcohol consumption.

Q: Does Leventa have a risk of dependence or withdrawal symptoms when stopped?

A: Regulatory documents do not mention drug dependence. However, abruptly stopping the medicine will result in the return of the original symptoms of hypothyroidism, as the body will no longer receive the necessary replacement hormone.

Q: What should I do if I notice a change in mood or behavior while taking Leventa?

A: Adverse reactions, particularly when related to over-replacement, include changes in the central nervous system. These documented changes include nervousness, anxiety, irritability, and emotional lability.

Q: Are there any studies focusing on Leventa use in older adults?

A: Yes, official regulatory documents contain specific sections addressing the use and monitoring of the medicine in older adults (geriatric population). They often note that a lower initial dose may be recommended for this group.

Q: Can people with kidney problems use Leventa?

A: Regulatory information indicates that the body's clearance of the medicine may be slowed in individuals with end-stage kidney disease who are undergoing dialysis. Patients are advised to discuss any kidney issues with their prescribing physician.

Q: How does the medicine Leventa get absorbed by the body?

A: The medicine is absorbed into the bloodstream primarily through the gastrointestinal tract. The amount absorbed can vary based on individual factors and whether the medicine is taken with certain foods or other substances.

Q: Are there different strengths of Leventa available?

A: Yes, the medicine is available in a wide variety of strengths, measured in micrograms (mcg), which allows for precise and individualized adjustments of the therapeutic amount.

Q: Is Leventa available in generic form?

A: Yes, the active substance, Levothyroxine Sodium, is available in generic formulations. These generic versions are recognized by regulatory authorities like the FDA as being therapeutically equivalent to the brand-name product.

Q: Does Leventa affect my ability to drive or operate machinery?

A: Based on the official adverse reaction profile, the medicine is not generally expected to impair the ability to drive. However, caution is advised if you experience nervous system effects such as dizziness or tremors.

Q: What is the estimated average duration of action for a single Leventa dose?

A: Official pharmacokinetic data indicates that the medicine has a relatively long average half-life in the body. The typical average half-life is approximately seven days in individuals with normal thyroid function.

Q: Can Leventa be used by women who are planning to become pregnant?

A: Thyroid hormone is essential for the health of both the mother and the developing fetus. Regulatory documents state that the medicine should be continued during pregnancy, and dose adjustments and close follow-up by a healthcare provider are often necessary.

Q: Does Leventa have a Black Box Warning, and what does it mean?

A: Yes, the product carries an FDA Boxed Warning (often referred to as a Black Box Warning). This warning specifically states that the medicine should not be used for the purpose of weight reduction or for the treatment of obesity.

Q: Are headaches a common side effect when starting Leventa?

A: Headache is explicitly listed in regulatory documents as a potential adverse reaction. It is typically associated with therapeutic overdosage rather than the typical starting phase of the treatment.

Q: Is Leventa known to interact with birth control pills?

A: Yes, oral contraceptives that contain estrogen can affect the proteins that bind thyroid hormone in the blood. This effect may increase the body's requirement for the medicine, and dose monitoring by a healthcare provider may be necessary.

Q: What is the typical patient profile for someone prescribed Leventa?

A: The medicine is primarily prescribed for individuals who have been diagnosed with an underactive thyroid, or hypothyroidism. It acts as a hormone replacement therapy for this condition.

Q: Can people with liver problems use Leventa?

A: The medicine is metabolized, or processed, mainly in the liver. While it is not a direct contraindication, regulatory information suggests that close monitoring may be necessary in the context of liver impairment.

How should Leventa be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal requirements for Leventa (Levothyroxine Sodium) are strictly defined by regulatory agencies to maintain product stability and ensure public safety.

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Avoid excess heat.
Environmental Protection Keep the medication in its original, tightly closed container. Protect from both light and moisture. Do not store in damp environments like a bathroom.
Child Safety Keep this medication strictly out of the sight and reach of children, preferably in a secured, locked location.
Stability Do not use the medicine past the expiration date (EXP) printed on the packaging.
Disposal Dispose of unused or expired medicine according to local requirements, such as drug take-back programs. Do not flush down a sink or toilet unless explicitly instructed to do so by a government authority.

These official rules ensure the medication retains its strength and prevent accidental access or environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Leventa found in:

A-Z Index: